Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Videos|November 8, 2013
Comparing Treatment Options in Ovarian Cancer
Author(s)James T. Thigpen, MD
James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
Advertisement
James T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Clinical Pearls
- In ovarian cancer studies, researchers cannot control what therapies a patient will receive following progression on a study therapy
- These additional lines of therapy have an impact on survival, making it difficult to make an accurate comparison of therapies
- Using progression-free survival (PFS) as an endpoint may allow for a clean comparison
Advertisement
Related to this article
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Dr Wang Highlights ESMO Lung Cancer Data Making an Impact
5